141 related articles for article (PubMed ID: 25144752)
1. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.
Zhang LL; Yang S; Wei W; Zhang XJ
Pharmacogenet Genomics; 2014 Nov; 24(11):531-8. PubMed ID: 25144752
[TBL] [Abstract][Full Text] [Related]
2. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
Taniguchi A; Urano W; Tanaka E; Akama H; Yamanaka H; Kamatani N
Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
[TBL] [Abstract][Full Text] [Related]
4. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
[TBL] [Abstract][Full Text] [Related]
8. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
Soejima M; Kawaguchi Y; Hara M; Kamatani N
J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
[No Abstract] [Full Text] [Related]
11. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
Kobayashi S; Kanai Y
Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Tanaka E; Taniguchi A; Urano W; Nakajima H; Matsuda Y; Kitamura Y; Saito M; Yamanaka H; Saito T; Kamatani N
J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
[TBL] [Abstract][Full Text] [Related]
15. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics in rheumatoid arthritis.
Sen D; Paul JR; Ranganathan P
Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
18. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
Mittal N; Mittal R; Sharma A; Jose V; Wanchu A; Singh S
Singapore Med J; 2012 Aug; 53(8):532-6. PubMed ID: 22941131
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
Castrejón I; Gibson KA; Pincus T
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside.
van der Heijden JW; Dijkmans BA; Scheper RJ; Jansen G
Nat Clin Pract Rheumatol; 2007 Jan; 3(1):26-34. PubMed ID: 17203006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
